Appello Pharmaceuticals, Inc.

In June 2018, Deerfield invested in Appello Pharmaceuticals Inc., an early stage spin-out from Vanderbilt University that is advancing a new small molecule therapy for the symptomatic treatment of Parkinson’s disease. The investment supports the development of the positive allosteric modulators (“PAMs”) of the metabotropic glutamate receptor subtype 4 (“mGlu4”).